Table 2. Characteristics of Treatment and Response^a.

Study/Protocol	Interferon Dose	Ribavirin Doses	Duration, w	Interferon Total Dose in Each Patient	Sustained Virological Response, %	End of Treatment Response, %
Inati et al.			48	8640 µg
Peg-IFN α-2a+placebo	180 µg/wk	-			33	42
Peg-IFN α-2a+ribavirin	180 µg/wk	10.6 mg/kg/d			62.5	75
Sood et al.			24 or 48	2160 - 4320 µg
Peg-IFN α-2b	1.5 µg/kg/wk	-			40	85
Peg-IFN α-2b+ribavirin	1.5 µg/kg/wk	15 mg/kg/d			70	85
Kalantar and Rad			24 or 48	216 – 432 million units
INF α-2b+placebo	9 million units/wk	-			55	61
INF α-2b+ribavirin	9 million units/wk	800 - 1200 mg/d			28.5	64

^aDrop out rate = 0%.